Abeona Therapeutics Inc

ABEO.US
Healthcare · Biotechnology
6.02
-0.11 (-1.79%)
USD · NASDAQ

Company Information

Company Name
Abeona Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US00289Y2063
CIK: 0000318306
CUSIP: 00431M308
Currency: USD
Full Time Employees: 226
Phone: 646 813 4701
Fiscal Year End: December
IPO Date: Sep 19, 1980
Description:

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.

Address:

6555 Carnegie Avenue, Cleveland, OH, United States, 44103

People

Directors & Officers

Name Title Year Born
Dr. Vishwas Seshadri M.B.A., Ph.D. President, CEO & Director 1976
Mr. Joseph Walter Vazzano CPA Chief Financial Officer 1984
Dr. Brendan M. O'Malley J.D., Ph.D. Chief Legal Officer 1969
Mr. Brian Kevany Ph.D. Chief Technical & Scientific Officer NA
Mr. Gregory Gin Vice President of Investor Relations & Corporate Communications NA
Ms. Gianine Esposito Senior VP & Chief People Officer NA
Mr. Jon Voss VP & Head of Quality 1960
Dr. Madhav Vasanthavada M.B.A., Ph.D. SVP, Chief Commercial Officer & Head of Business Development 1979
Mr. Carl Denny Senior Vice President of Regulatory Affairs NA
Ms. Megan Callan Vice President & Head of Quality NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Feb 02, 2026 Eric Crombez N/A Sale 16.28K $5.09 $82.89K
Feb 02, 2026 Leila Alland N/A Sale 18.07K $5.09 $91.95K
Feb 02, 2026 Mark Alvino N/A Sale 2.00K $5.09 $10.18K
Feb 02, 2026 Christine Berni Silverstein N/A Sale 20.07K $5.09 $102.16K
Jan 22, 2026 Brendan M O'malley N/A Sale 13.58K $5.33 $72.37K
Jan 22, 2026 Joseph Walter Vazzano N/A Sale 18.67K $5.33 $99.49K
Jan 22, 2026 Madhav Vasanthavada N/A Sale 12.61K $5.29 $66.71K
Jan 22, 2026 Vishwas Seshadri N/A Sale 69.83K $5.33 $372.20K
Jan 21, 2026 Mark Alvino N/A Sale 13.50K $5.23 $70.61K
Dec 29, 2025 Vishwas Seshadri N/A Sale 25.00K $5.31 $132.75K
Nov 13, 2025 Mark Alvino N/A Sale 15.00K $4.74 $71.10K
Oct 16, 2025 Vishwas Seshadri N/A Sale 249.00 $5.49 $1.37K
Sep 30, 2025 Vishwas Seshadri N/A Sale 25.00K $5.24 $131.00K
Sep 29, 2025 Joseph Walter Vazzano N/A Sale 9.04K $5.39 $48.70K
Sep 29, 2025 Vishwas Seshadri N/A Sale 19.27K $5.39 $103.89K
Sep 29, 2025 Brendan M O'malley N/A Sale 9.37K $5.39 $50.48K
Sep 22, 2025 Brendan M O'malley N/A Sale 688.00 $5.43 $3.74K
Jul 22, 2025 Joseph Walter Vazzano N/A Sale 1.50K $6.64 $9.97K
Jul 09, 2025 Brendan M O'malley N/A Sale 17.43K $5.86 $102.13K
Jul 09, 2025 Christine Berni Silverstein N/A Sale 13.09K $5.86 $76.72K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Nantahala Capital Management, LLC 5.01M Mar 31, 2026 8.80% $0.83 1.01%
BlackRock Inc 3.20M Mar 31, 2026 5.61% $0.00 1.13%
AIGH Capital Management, LLC 3.10M Mar 31, 2026 5.44% $1.89 55.00%
Cable Car Capital LLC 3.01M Mar 31, 2026 5.28% $4.65 20.29%
Vanguard Group Inc 2.76M Dec 31, 2025 4.84% $0.00 5.93%
Suvretta Capital Management, LLC 2.68M Mar 31, 2026 4.70% $0.31 0.00%
Vanguard Capital Management, LLC 2.16M Mar 31, 2026 3.80% $0.00 0.00%
Propel Bio Management LLC 1.33M Mar 31, 2026 2.33% $3.79 60.08%
Kennedy Capital Management Inc 1.26M Mar 31, 2026 2.22% $0.12 20.32%
Geode Capital Management, LLC 1.21M Mar 31, 2026 2.12% $0.00 6.39%
The Goldman Sachs Group Inc 1.13M Mar 31, 2026 1.98% $0.00 125.14%
State Street Corp 957.33K Mar 31, 2026 1.68% $0.00 6.55%
NAN FUNG TRINITY (HK) Ltd 956.77K Mar 31, 2026 1.68% $0.47 0.00%
Awm Investment Company Inc 803.13K Mar 31, 2026 1.41% $0.40 3.75%
683 Capital Management LLC 770.00K Mar 31, 2026 1.35% $0.18 0.00%
Stonepine Capital Management Llc 746.59K Mar 31, 2026 1.31% $1.34 5.23%
SILVERARC CAPITAL MANAGEMENT, LLC 648.94K Mar 31, 2026 1.14% $0.30 3.38%
J. Goldman & Co LP 640.53K Mar 31, 2026 1.12% $0.08 60.57%
Diametric Capital, LP 611.52K Mar 31, 2026 1.07% $0.71 -11.94%
Balyasny Asset Management LLC 589.85K Mar 31, 2026 1.03% $0.00 -0.32%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Total Stock Mkt Idx Inv 1.53M 2.68% ▲ 0.00% Jun 30, 2026
2 iShares Russell 2000 ETF 1.19M 2.09% ▲ 0.60% Jun 30, 2026
3 Kennedy Micro Cap 767.11K 1.35% ▼ 12.29% Jun 30, 2026
4 Vanguard Institutional Extnd Mkt Idx Tr 627.77K 1.10% ▲ 8.40% Jun 30, 2026
5 Fidelity Small Cap Index 456.62K 0.80% ▲ 0.88% Apr 30, 2026
6 iShares Russell 2000 Value ETF 406.75K 0.71% ▼ 0.69% Jun 30, 2026
7 Kennedy Micro Cap Opportunities 381.16K 0.67% ▼ 1.52% Jun 30, 2026
8 Simplify Propel Opportunities ETF 345.42K 0.61% ▲ 0.00% Jun 30, 2026
9 Russell 2000 Index Non-Lendable Fund 287.77K 0.50% ▼ 0.23% Jun 30, 2026
10 Russell 2000 Equity Index Fund B 287.77K 0.50% ▼ 0.23% Jun 30, 2026

Financial Highlights

Market Cap: $349.38M
EBITDA: $-90.05M
P/E Ratio: $6.39
PEG Ratio: $0.00
Book Value: $2.55
Earnings/Share: $0.96
Profit Margin: 454.86%
Operating Margin: -264.14%
ROA (TTM): -38.92%
ROE (TTM): 70.99%
Revenue (TTM): $14.54M
Revenue/Share (TTM): $0.27
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -100.00%

Valuation Metrics

Enterprise Value: $200.29M
Trailing P/E: 6.39
Forward P/E: 526.32

Shares Statistics

Shares Outstanding: 57.00M
Shares Float: 36.62M
% Insiders: 1,654.20%
% Institutions: 7,039.90%
Short % Float: 24.93%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$5.82M
Cost of Goods Sold
adjust
$-1.53M
Gross Profit
subtotal
$4.29M
SG&A
adjust
$-65.03M
R&D
adjust
$-26.81M
Other Operating Expense
adjust
$-1.89M
Operating Income
subtotal
$-89.45M
Other / Non-Operating Items
adjust
$160.63M
Net Income
subtotal
$71.18M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about ABEO.US!